JAMA Network
About The Study: In this nationwide cohort of U.S. veterans with type 2 diabetes, semaglutide initiators had a 2-fold nonarteritic anterior ischemic optic neuropathy (NAION) risk than sodium-glucose cotransporter-2 inhibitor initiators, while the absolute risk was low. Clinicians and patients should be counseled on the rare but evident increased risk of NAION after semaglutide initiation.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
